Abstract
Systemic sclerosis is a multisystem autoimmune disease with potential lung manifestations that include pulmonary vascular and interstitial disease. Not only is interstitial lung disease the most common pulmonary manifestation, it is a major cause of morbidity and mortality in patients with systemic sclerosis. The risk of systemic sclerosis patients developing progressive interstitial lung disease is strongly associated with the presence of certain autoantibodies The most common lung injury pattern observed in systemic sclerosis-related interstitial lung disease is the fibrotic variant of nonspecific interstitial pneumonia. Because scleroderma renal crisis can now be effectively treated, recently, focus has turned toward how best to treat systemic sclerosis-related interstitial lung disease. Therapy usually involves an immunomodulatory regimen consisting of a steroid-sparing agent with or without glucocorticoids, and response to therapy is variable.
Keywords: Systemic sclerosis, scleroderma, pulmonary fibrosis, lung diseases, interstitial
Current Respiratory Medicine Reviews
Title: Systemic Sclerosis-Related Interstitial Lung Disease
Volume: 4 Issue: 3
Author(s): Samay Dalal, Aryeh Fischer and Jeffrey J. Swigris
Affiliation:
Keywords: Systemic sclerosis, scleroderma, pulmonary fibrosis, lung diseases, interstitial
Abstract: Systemic sclerosis is a multisystem autoimmune disease with potential lung manifestations that include pulmonary vascular and interstitial disease. Not only is interstitial lung disease the most common pulmonary manifestation, it is a major cause of morbidity and mortality in patients with systemic sclerosis. The risk of systemic sclerosis patients developing progressive interstitial lung disease is strongly associated with the presence of certain autoantibodies The most common lung injury pattern observed in systemic sclerosis-related interstitial lung disease is the fibrotic variant of nonspecific interstitial pneumonia. Because scleroderma renal crisis can now be effectively treated, recently, focus has turned toward how best to treat systemic sclerosis-related interstitial lung disease. Therapy usually involves an immunomodulatory regimen consisting of a steroid-sparing agent with or without glucocorticoids, and response to therapy is variable.
Export Options
About this article
Cite this article as:
Dalal Samay, Fischer Aryeh and Swigris J. Jeffrey, Systemic Sclerosis-Related Interstitial Lung Disease, Current Respiratory Medicine Reviews 2008; 4 (3) . https://dx.doi.org/10.2174/157339808785161332
DOI https://dx.doi.org/10.2174/157339808785161332 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Diagnostic and Prognostic Potential of the Macrophage Specific Receptor CD163 in Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Novel Aspects in the Pathophysiology of Peripheral Vasculopathy in Systemic Sclerosis
Current Rheumatology Reviews Intravenous Immunoglobulin (IVIG) in Rheumatologic Diseases: A Review of its Mechanism of Action
Current Rheumatology Reviews Viral Anti-Inflammatory Reagents: The Potential for Treatment of Arthritic and Vasculitic Disorders
Endocrine, Metabolic & Immune Disorders - Drug Targets Pharmacologic Ovarian Preservation in Young Women Undergoing Chemotherapy
Current Medicinal Chemistry Editorial from Editor-in-Chief
Current Rheumatology Reviews TGF-β: Its Role in Asthma and Therapeutic Potential
Current Drug Targets Regulation of TGF-β Signaling by SMADs and its Roles in Tissue Fibrosis
Current Signal Transduction Therapy Contribution of Mast Cells to Cerebral Aneurysm Formation
Current Neurovascular Research Insights on Biology and Pathology of HIF-1α/-2α, TGFβ/BMP, Wnt/β-Catenin, and NF-κB Pathways in Osteoarthritis
Current Pharmaceutical Design Mechanisms Leading to Autoantibody Production: Link Between Inflammation and Autoimmunity
Current Drug Targets - Inflammation & Allergy Update on Intravenous Immunoglobulins (IVIg) Mechanisms of Action and Off- Label use in Autoimmune Diseases
Current Pharmaceutical Design Advances in Chondroitin Sulfate Analysis: Application in Physiological and Pathological States of Connective Tissue and During Pharmacological Treatment of Osteoarthritis
Current Pharmaceutical Design The Effectiveness of Topical Anti-scarring Agents and a Novel Combined Process on Cutaneous Scar Management
Current Pharmaceutical Design Heat Shock Proteins: Therapeutic Perspectives in Inflammatory Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Recent Advances in the Treatment of Interstitial Lung Disease in Patients with Polymyositis/Dermatomyositis
Endocrine, Metabolic & Immune Disorders - Drug Targets Breast Reconstruction – A Historical Perspective on Available Techniques for Patients Electing Bilateral Mastectomy
Current Cancer Therapy Reviews A Literature Review of Eosinophilic Fasciitis with an Illustrative Case
Current Rheumatology Reviews The Idiopathic Interstitial Pneumonias and Connective Tissue Disease-Associated Interstitial Lung Disease
Current Rheumatology Reviews Immunobiologic Agents in Dermatology
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry